Research on healthcare disparities, infantile spasms, and psychogenic seizures.

View this email in your browser ([link removed])

CURE Epilepsy is dedicated to funding patient-focused research to find a cure for the 65 million people with epilepsy worldwide. This month, we share the following articles and abstracts which are furthering the study of epilepsy and bringing the world closer to a cure.

This issue of Epilepsy Research News includes summaries of articles on:
* Infantile Spasms: Speeding Referrals for All Infants ([link removed])
* Fintepla Safely Reduces Seizures in Children Younger than 2, Study Finds ([link removed])
* Death Rate Higher than Expected for Patients with Functional, Nonepileptic Seizures ([link removed])


** Infantile Spasms: Speeding Referrals for All Infants
------------------------------------------------------------

Infantile epileptic spasms syndrome (IESS), often called infantile spasms (IS), is the most common form of epilepsy seen during infancy. Prompt diagnosis and referral to a neurologist are essential. A recent study found that Black children and children with public insurance are less likely to receive a standard treatment course for IESS. This prompted Boston Children’s neurology fellow Christina Briscoe Abath, MD, and her mentor Chellamani Harini, MD, to take a closer look at care for IS in infants from historically marginalized racial/ethnic backgrounds and create a new open-access training module for front-line providers in OPENPediatrics, an online learning community.
Learn More ([link removed])


** Fintepla Safely Reduces Seizures in Children Younger than 2, Study Finds
------------------------------------------------------------

Treatment with Fintepla (fenfluramine) appeared to be reasonably safe and lower seizure frequency in five children with Dravet syndrome who started on the therapy before they were two years old, scientists in Italy reported. These findings are noteworthy because in the US and European Union, Fintepla is approved for Dravet patients ages two and older.
Learn More ([link removed])


** Death Rate Higher than Expected for Patients with Functional, Nonepileptic Seizures
------------------------------------------------------------

The death rate for patients with functional, nonepileptic seizures is higher than expected, with a rate comparable to epilepsy and severe mental illness, a Michigan Medicine-led study finds. In the largest study of its kind in the United States, a team of researchers reviewed data from 700 patients diagnosed with functional seizures, also called psychogenic or nonepileptic seizures. Of the 700 patients with functional seizures, 11 of them died — a death rate almost 2.5 times the number of people who would be expected to die over the same time period among similar people without functional seizures.
Learn More ([link removed])


** Check Out Our Latest:
------------------------------------------------------------
[link removed]


** Seizing Life Podcast ([link removed])
------------------------------------------------------------
[link removed]


** Epilepsy Explained Episode ([link removed])
------------------------------------------------------------
[link removed] [link removed] [link removed] [link removed] [link removed] [link removed]
[link removed]

Today's research has the ability to help
the 65 million people worldwide who are impacted by epilepsy every day.
And each one of those individuals has a story.
Read Jim's story ([link removed])
[link removed]

Our mission is to find a cure for epilepsy, by promoting and funding patient-focused research.

CURE Epilepsy is a non-profit 501(c)(3) tax-exempt organization. Our tax identification number is 36-4253176.

Copyright (C) 2024 CURE Epilepsy. All rights reserved.
In the past you provided CURE Epilepsy your email address. Occasionally, you will receive updates from us about epilepsy research and news.
Our mailing address is:
CURE Epilepsy
420 Wabash Ave, Ste 650
Chicago, IL 60611
USA
Want to change how you receive these emails?
You can update your preferences ([link removed]) or unsubscribe ([link removed])